This page contains a Flash digital edition of a book.
Dokras_edit.qxp 5/10/07 09:54 Page 12
Polycystic Ovary Syndrome
decrease in visceral adiposity over the 12-month period. Comparable improving the likelihood of becoming pregnant. Compliance with
improvement in menstrual function was noted in both groups in the first weight-loss regimens is, however, a widely recognized problem and was
six months. Interestingly, this study also included a group of subjects noted in many of the studies. Fortunately, there is evidence that small to
randomized to metformin and flutamide (n=20); these women had moderate amounts of weight loss improve reproductive, endocrine, and
significant improvement in menstrual cyclicity up to 12 months. metabolic profiles in women with PCOS. However, we urgently need
studies in women with PCOS that answer the following questions: does
From these three randomized trials, it appears that lifestyle modifications weight loss improve pregnancy and live birth rates, and would lifestyle
along with metformin therapy for at least six months improves body fat interventions with or without metformin be more effective in a particular
distribution, insulin sensitivity, and menstrual function. There may be BMI range? Given the difficulties with achieving and maintaining weight
beneficial effects of metformin beyond those explained by weight loss loss, studies using pharmacotherapy as an adjunct to hypocaloric diets
alone. In fact, prolonged dietary changes may be associated with a are also urgently needed in this population. The combination of lifestyle
decrease in visceral adiposity rather than a decrease in BMI, with an modification and pharmacotherapy results in greater weight loss than
overall positive effect on metabolic and reproductive end-points. either alone. In counseling these patients, one must emphasize the
positive impact of weight loss beyond the reproductive system, including
Conclusion lower obstetric risks and a reduction in the long-term risk of diabetes,
This article suggests that weight loss is a simple, cost-effective way of hypertension, hyperlipidemia, and coronary artery disease. ■
1. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al., Prevalence of Clin Endocrinol (Oxf), 1990;32(2):213–20. fertility rate induced by diet, Hum Reprod, 2003;18:1928–32.
the polycystic ovary syndrome in unselected black and white 16. Pasquali R, Casimirri F, Cantobelli S, et al., Beta-endorphin 31. Kiddy DS, Hamilton-Fairley D, Bush A, et al., Improvement in
women of the southeastern United States: a prospective study, J response to exogenous corticotrophin-releasing hormone in endocrine and ovarian function during dietary treatment of obese
Clin Endocrinol Metab, 1998;83:3078–82. obese women with different patterns of body fat distribution, Int women with polycystic ovary syndrome, Clin Endocrinol (Oxf),
2. Setji TL, Brown AJ, Polycystic ovary syndrome: diagnosis and J Obes Relat Metab Disord, 1993;17(10):593–6. 1992;36(1):105–11.
treatment, Am J Med, 2007;120:128–32. 17. Dunaif A, Segal KR, Futterweit W, Dobrjansky A, Profound 32. Huber-Buchholz MM, Carey DG, Norman RJ, Restoration of
3. Ehrmann DA, Polycystic ovary syndrome, N Engl J Med, peripheral insulin resistance, independent of obesity, in polycystic reproductive potential by lifestyle modification in obese polycystic
2005;352:1223–36. ovary syndrome, Diabetes, 1989;38(9):1165–74. ovary syndrome: role of insulin sensitivity and luteinizing
4. Stein IL, Leventhal ML, Amenorrhea associated with bilateral 18. Norman RJ, Kidson WJ, Cuneo RC, Zacharin MR, Metformin and hormone, J Clin Endocrinol Metab, 1999;84(4):1470–74.
polycystic ovaries, Am J Obstet Gynecol, 1935;29:181–91. intervention in polycystic ovary syndrome. Endocrine Society of 33. Despres JP, Lemieux I, Prud’homme D, Treatment of obesity:
5. Legro RS, Blanche P, Krauss RM, Lobo RA, Alterations in low- Australia, the Australian Diabetes Society and the Australian need to focus on high risk abdominally obese patients, BMJ,
density lipoprotein and high-density lipoprotein subclasses Paediatric Endocrine Group, Med J Aust, 2001;174(11):580–83. 2001;322(7288):716–20.
among Hispanic women with polycystic ovary syndrome: 19. Cresswell JL, Barker DJ, Osmond C, et al., Fetal growth, length of 34. Moran C, Garcia-Hernandez E, Barahona E, et al., Relationship
influence of insulin and genetic factors, Fertil Steril, gestation and polycystic ovaries later in adult life, Lancet, between insulin resistance and gonadotropin dissociation in
1999;72(6):990–95. 1997;350:1131–5. obese and nonobese women with polycystic ovary syndrome,
6. Wild RA, Painter PC, Coulson PB, et al., Lipoprotein lipid 20. Gesink Law DC, Maclehose RF, Longnecker MP, Obesity and time Fertil Steril, 2003;80(6):1466–72.
concentrations and cardiovascular risk in women with polycystic to pregnancy, Hum Reprod, 2007;22(2):414-20. Epub 2006 Nov 35. Stamets K, Taylor DS, Kunselman A, et al., A randomized trial of
ovary syndrome, J Clin Endocrin Metab, 1985; 61(5);946–51. 9. the effects of two types of short-term hypocaloric diets on weight
7. Dokras A, Bochner M, Hollinrake E, et al., Screening women with 21. Lake JK, Power C, Cole TJ, Child to adult body mass index in the loss in women with polycystic ovary syndrome, Fertil Steril,
polycystic ovary syndrome for metabolic syndrome, Obstet 1958 British birth cohort: associations with parental obesity, Arch 2004;81(3):630–37.
Gynecol, 2005;106(1):131–7. Dis Child, 1997;77(5):376–81. 36. Pasquali R, Casimirri F, Colella P, Melchionda N, Body fat
8. Dokras A, Jagasia DH, Maifeld M, et al., Obesity/insulin resistance 22. Pasquali R, Gambineri A, Pagotto U, The impact of obesity on distribution and weight loss in obese women, Am J Clin Nutr,
but not hyperandrogenism is an important mediator of vascular reproduction in women with polycystic ovary syndrome, BJOG, 1989;49(1):185–7.
dysfunction in women with PCOS, Fertil Steril, 2006;86(6): 2006;113:1148–59. 37. Clark AM, Thornley B, Tomlinson L, et al., Weight loss in obese
1702–9. 23. Dokras A, Baredziak J, Blaine J, et al., Obstetric Outcomes After In infertile women results in improvement in reproductive outcome
9. Zawadski JK, Dunaif A, Diagnostic criteria for polycystic ovary Vitro Fertilization in Obese and Morbidly Obese Women, Obstet for all forms of fertility treatment, Hum Reprod, 1998;13(6):
syndrome: towards a rational approach. In: Dunaif A, Givens JR, Gynecol, 2006;108(1):61–9. 1502–5.
Haseltine F (eds), Polycystic Ovary Syndrome, Boston: Blackwell 24. Lashen H, Ledger W, Bernal AL, Barlow D, Extremes of body mass 38. De Leo V, la Marca A, Petraglia F, Insulin-lowering agents in the
Scientific, 1992:377–84. do not adversely affect the outcome of superovulation and in management of polycystic ovary syndrome, Endocr Rev,
10. Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop vitro fertilization, Hum Reprod, 1999;14;712–15. 2003;24:633–7.
Group, Revised 2003 consensus on diagnostic criteria and long- 25. Spandorfer SD, Kump L, Goldschlag D, et al., Obesity and in vitro 39. Pasquali R, Gambineri A, Biscotti D, et al., Effect of long-term
term health risks related to polycystic ovary syndrome, Fertil fertilization: negative influences on outcome, J Reprod Med, treatment with metformin added to hypocaloric diet on body
Steril, 2004;81:19–25. 2004;49;973–7. composition, fat distribution, and androgen and insulin levels in
11. Franks S, McCarthy MI, Hardy K, Development of polycystic ovary 26. Lobo R, Gysler M, March CM, et al., Clinical and laboratory abdominally obese women with and without the polycystic ovary
syndrome: involvement of genetic and environmental factors, Int J predictors of clomiphene response, Fertil Steril, 1982;37:168–74. syndrome, J Clin Endocrinol Metab, 2000;85(8):2767–74.
Androl, 2006;29(1):278–85; discussion 286–90. Epub 2005 Dec 27. Legro RS, Barnhart HX, Schlaff WD, et al., Cooperative 40. Hoeger KM, Kochman L, Wixom N, et al., A randomized, 48-week,
22. Review. Multicenter Reproductive Medicine Network. Clomiphene, placebo-controlled trial of intensive lifestyle modification and/or
12. Abbott DH, Barnett DK, Bruns CM, Dumesic DA, Androgen excess metformin, or both for infertility in the polycystic ovary syndrome, metformin therapy in overweight women with polycystic ovary
fetal programming of female reproduction: a developmental N Engl J Med, 2007;356(6):551–66. syndrome: a pilot study, Fertil Steril, 2004;82(2):421–9.
aetiology for polycystic ovary syndrome?, Hum Reprod Update, 28. Hamilton-Fairley D, Kiddy D, Watson H, et al., Association of 41. Tang T, Glanville J, Hayden CJ, et al., Combined lifestyle
2005;11(4):357–74. Review. moderate obesity with a poor pregnancy outcome in women with modification and metformin in obese patients with polycystic
13. Dunaif A, Insulin resistance and the polycystic ovary syndrome: polycystic ovary syndrome treated with low dose gonadotrophin, ovary syndrome. A randomized, placebo-controlled, double-blind
mechanism and implications for pathogenesis, Endocr Rev, Br J Obstet Gynaecol, 1992;99(2):128–31 multicentre study, Hum Reprod, 2006;21(1):80–89. Epub 2005
1997;18:774–800. 29. White DM, Polson DW, Kiddy D, et al., Induction of ovulation with Sep 30.
14. Gambineri A, Pelusi C, Vicennati V, et al., Obesity and the low-dose gonadotropins in polycystic ovary syndrome: an analysis 42. Gambineri A, Patton L, Vaccina A, et al., Treatment with
polycystic ovary syndrome, Int J Obes Rel Metab Disord, of 109 pregnancies in 225 women, J Clin Endocrinol Metab, flutamide, metformin, and their combination added to a
2002;26:883–96. 1996;81(11):3821–4. No abstract available. hypocaloric diet in overweight-obese women with polycystic
15. Kiddy DS, Sharp PS, White DM, et al., Differences in clinical and 30. Crosignani PG, Colombo M, Vegetti W, et al., Overweight and ovary syndrome: a randomized, 12-month, placebo-controlled
endocrine features between obese and non-obese subjects with obese anovulatory patients with polycystic ovaries: parallel study, J Clin Endocrinol Metab, 2006;91(10):3970–80. Epub 2006
polycystic ovary syndrome: an analysis of 263 consecutive cases, improvements in anthropometric indices, ovarian physiology and Jul 25.
12 FERTILITY TREATMENT REVIEW
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35
Produced with Yudu - www.yudu.com